NeuroSense Therapeutics Ltd. operates in pharmaceutical preparations and trades on Nasdaq under the ticker NRSNW. The company provides products or services connected to this market, with its SEC filings providing the primary details of its business operations. This automatic page tracks its financial results, SEC filings, company news, market price, and technical setup while full editorial research is pending.
The stock may not have enough completed daily history yet. This panel will retry automatically and activate as soon as a reliable 200-day EMA can be calculated.
Form 4 reports insider transactions. Schedule 13D and 13G filings report certain significant ownership positions. 13F reports institutional holdings when filed by an investment manager. Always open the original filing for context.
This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.
Market cap estimate$2.28MMicro cap
Price / salesUnavailableLatest reported fiscal year
Price / earningsN/MLatest reported fiscal year
Net marginUnavailableNet income ÷ revenue
Five-year filing history
Financial performance charts
Annual values from SEC filings. Free cash flow is calculated as operating cash flow less capital expenditures.
RevenueNot reported
The SEC filing feed did not return a consistent annual series for this metric.
Net income-$11.1M-9.0% YoY
Operating cash flow-$7.7M
Research coverage
Full Rithvik analysis coming soon
The live data and primary-source filings above update automatically. A full business, catalyst, risk, valuation, and final-view report will appear here after Rithvik completes and publishes the research.
Data updatedLatest availableCompleted daily market candle
Source qualityPrimary SEC filingsMarket feeds may be delayed
Disclaimer
This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market and filing data is provided by third-party and public sources and may be delayed, incomplete, or inaccurate. Automatically calculated figures are estimates and have not been manually verified. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.
+24.3% YoY
Free cash flow-$7.7M+24.3% YoY
Net marginNot reported
The SEC filing feed did not return a consistent annual series for this metric.
